Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function

Phase 4 Unknown 100 enrolled Sun Yat-sen University

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate and evaluate the effects of liraglutide combined with short-term continuous subcutaneous insulin infusion(CSII) on long-term glycemic control and β-cell function in newly diagnosed type 2 diabetic patients.

Timeline

Start: 2013-02
Primary completion: 2014-12
Completion: 2015-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Liraglutide	Peptide	0.6 mg	—
Comparator	Liraglutide	Peptide	1.2 mg	—

Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function

Summary

Timeline

Drugs

Indications